Myeloid Therapeutics to Participate in Jefferies London Healthcare Conference

CAMBRIDGE, Mass. , Nov. 13, 2024 /PRNewswire/ -- Myeloid Therapeutics, Inc.

("Myeloid"), a clinical-stage immunology company advancing RNA therapeutics to conquer cancer, announced today its participation at the Jefferies London Healthcare Conference, taking place November 19-21, 2024 . Company management will participate in one-on-one meetings with investors and B2B meetings during the conference. About Myeloid Therapeutics Myeloid Therapeutics is a clinical stage immunology company, engineering cutting-edge RNA technology to program immune cells to combat cancer and other deadly diseases.

Myeloid is headquartered in Cambridge, MA. For additional information, please visit, https://www.myeloidtx.

com/ and follow us on LinkedIn and X/Twitter . For collaborative interests, write to [email protected] . Investor Contact Amy Conrad Juniper Point [email protected] SOURCE Myeloid Therapeutics, Inc.

.